Natural Science > Biology > DG CY2020 8098

Research Title Anti-Hyperuricemic Bioactive Hits from Priority Plant Extracts (Year 2 of 2)
Research Personnel Leader:
Staff:


Research Duration Start:
End:
1 August 2019
3 July 2021
Research Location PLI
Research Description Hyperuricemia which is associated with gout is a condition affecting 5-30% of the general population (1). Researches on natural products show that a vast number of compounds with xanthine oxidase inhibitory effect can be pooled and potentially developed into drugs for the treatment of gout and other diseases associated with xanthine oxidase (OX) activity. The proposed project aims to prioritize extracts with XO inhibitory activity based on results of orthogonal assays, toxicity and mass spectrometry profiles. Priority extracts are nontoxic with positive orthogonal assays and with high probability of obtaining new compounds.
Research Objectives The project generally aims to bridge this gap in combating gout and other XOrelated disorders by isolating antihyperuricemic bioactive hits from priority plant extracts. The project has the following specific objectives: 1.To isolate pure compounds from priority (non-toxic and highest activity) plant extracts using xanthine oxidase inhibitory (XOI) activity guided chromatographic techniques; 2.To validate the uric acid lowering property of the pure isolates using a secondary readout model/orthogonal test for XOI; and 3.To elucidate structures of the most bioactive (>60% inhibition, IC50 lower than standard) hits through spectroscopic techniques including HRMS-MS and NMR (1D and 2D)
Research Beneficiary(ies) 1. Biotechnology, pharmaceutical companies, and other private investors who will commercialize the products after the technology transfer. 2. Patients diagnosed with hyperuricemia which may lead to gout and cardiovascular diseases.
Research Accoplishments [CY 2019] The specific expected outputs are: 1) Bioactive pure compounds with anti-gout activity from priority bioactive extracts; 2) Patents and/or publications of novel plant-based XO inhibitors; 3) Industry integrated R&D facility for innovating new therapeutics sourced from natural products; 4) Personnel equipped with R&D capabilities; and 5) Policies for the conduct of sound and ethical R&D.
Total Research Cost ₱1,381,963.60
Research Agencies Funding:
Implementing:
Cooperating:
Monitoring:

PLI


Research Budget Breakdown Year:
Year Funded:
PS:
MOOE:
EO:
Total Cost
Date Released
Amount Released








Code DG CY2020 8098
KRA Code
Priority Thrust DOST
R&D


Sector Natural Sciences
Actual Sector Plant Science
Related sectors Chemistry
Entry revision: February 2021